SCHEMBL7045694

SCHEMBL7045694

CCOc1ccc(CC(=O)Nc2cc(C)nc3c(-c4c(C)cc(C)cc4C)c(C)nn23)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 3/20 0.50
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.47
CYP3A4 P08684 1/20 0.47
ADORA2A P29274 1/20 0.47
TP53 P04637 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
MAPK10 P53779 1/20 0.43
HTT P42858 1/20 0.43
EPHX2 P34913 1/20 0.43
ATM Q13315 2/20 0.43
ALPL P05186 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045715 0.86 NPY1R (0.64) NPY1RALDH1A1KDM4ECYP3A4ADORA2A
SCHEMBL7042428 0.81 NPY1R (0.74) NPY1RALDH1A1KDM4EMAPTHPGD
SCHEMBL7041881 0.68 NPY1R (0.61) NPY1RALDH1A1KDM4EMAPTHPGD
SCHEMBL7044237 0.67 NPY1R (1.00) NPY1RALDH1A1KDM4EMAPTHPGD
SCHEMBL3706186 0.67 KCNQ3 (0.57) ALDH1A1KDM4EMAPTHPGDADORA2A
SCHEMBL5611176 0.66 CRHR1 (0.65) NPY1RCRHR1
SCHEMBL1594052 0.66 NPY1R (0.66) NPY1RALDH1A1KDM4EMAPTHPGD
SCHEMBL16934991 0.66 MAPT (0.57) ALDH1A1KDM4EMAPTHPGDTP53
SCHEMBL16935032 0.66 MAPT (0.65) ALDH1A1KDM4EMAPTHPGDTP53
SCHEMBL16935011 0.66 MAPT (0.59) ALDH1A1KDM4EMAPTHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069246-A1 Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines NEUROGEN CORPORATION (US) 2003-04-10 US disclosed
EP-1218379-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES NEUROGEN CORPORATION (US) 2002-07-03 EP disclosed
US-6372743-B1 EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2002-04-16 US disclosed
WO-2001023387-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES NEUROGEN CORPORATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069246-A1 Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines NPY1R, NPY5R, NPY2R NPY1R 1/4885ALDH1A1 2283/4885KDM4E 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.